An expert in intellectual property laws told ET that the order may require Dr Reddy’s Labs to explain the grounds for exports of weight-loss drug semaglutide.
The court’s directive comes on the back of a plea by Novo Nordisk, which alleged patent infringement. The patent for the weight-loss drug is slated to end in March next year.